Circulating CD36+ microparticles are not altered by docosahexaenoic or eicosapentaenoic acid supplementation

Nutr Metab Cardiovasc Dis. 2016 Mar;26(3):254-60. doi: 10.1016/j.numecd.2015.12.003. Epub 2015 Dec 18.

Abstract

Background and aims: Circulating microparticles (MP) are the source of a plasma derived form of the scavenger receptor CD36, termed soluble (s)CD36, the levels of which correlate with markers of atherosclerosis and risk of cardiovascular disease. Long chain n-3 polyunsaturated fatty acids have cardioprotective effects that we have previously reported to be gender specific. The aim of this study was to determine if dietary docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA) supplementation affect circulating CD36 + MP levels, and if this occurs differentially in healthy men and women.

Methods and results: Participants (43M, 51F) aged 39.6 ± 1.7 years received 4 weeks of daily supplementation with DHA rich (200 mg EPA; 1000 mg DHA), EPA rich (1000 mg EPA; 200 mg DHA), or placebo (sunola) oil in a double-blinded, randomised, placebo controlled trial. Plasma CD36 + MP were enumerated by flow cytometry and differences between genders and treatments were evaluated by Student's or paired t-test and one way ANOVA. Males and females had similar levels of CD36 + MP at baseline (mean = 1018 ± 325 vs 980 ± 318; p = 0.577) and these were not significantly changed after DHA (M, p = 0.571; F, p = 0.444) or EPA (M, p = 0.361; F, p = 0.901) supplementation. Likewise, the overall percent change in these levels were not different between supplemented cohorts compared to placebo when all participants were combined (% change in CD36 + MP: DHA = 5.7 ± 37.5, EPA = -3.4 ± 35.4, placebo = -11.5 ± 32.9; p = 0.158) or stratified by gender (M, DHA = -2.6 ± 30.6, EPA = -15.1 ± 20.1, placebo = -21.4 ± 28.7, p = 0.187; F, DHA = 11.7 ± 41.5, EPA = 6.8 ± 42.9, placebo = -2.8 ± 34.7, p = 0.552).

Conclusion: The cardioprotective effects of DHA and EPA do not act through a CD36 + MP mechanism.

Keywords: CD36; Docosahexaenoic acid; Eicosapentaenoic acid; Microparticles; Polyunsaturated fatty acids; Scavenger receptor.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / blood
  • Body Mass Index
  • CD36 Antigens / blood*
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / drug therapy
  • Cell-Derived Microparticles / drug effects*
  • Dietary Supplements*
  • Docosahexaenoic Acids / administration & dosage*
  • Docosahexaenoic Acids / blood
  • Double-Blind Method
  • Eicosapentaenoic Acid / administration & dosage*
  • Eicosapentaenoic Acid / blood
  • Female
  • Fish Oils / administration & dosage
  • Humans
  • Male
  • Middle Aged
  • Particle Size
  • Treatment Outcome
  • Young Adult

Substances

  • Biomarkers
  • CD36 Antigens
  • Fish Oils
  • Docosahexaenoic Acids
  • Eicosapentaenoic Acid

Associated data

  • ANZCTR/ACTRN12611000098932